VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
Biopharma & Life Sciences

Aurinia Pharmaceuticals Executive Compensation (FY25)

AUPH · Executive and director compensation, fiscal 2022 to 2025
Latest say-on-pay support
=
June 3, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing

The Aurinia Pharmaceuticals brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
Data as of November 5, 2026Latest filing (8-K): June 4, 2026
8 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Aurinia Pharmaceuticals brief$500Get the executive brief
Velarion Intel, one year, every company
273 figures on this page: 267 cited to the filing that reported them, 6 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Peter Greenleaf: $6,417,897 → $5,858,590 (8.7% lower)
Say-on-pay support: 77.4% → 93.9% (16.5 points higher)
CEO pay ratio: 33:1 → 18:1 (45.5% lower)

Frequently asked questions

Answers drawn from the data on this page.
What was Aurinia Pharmaceuticals' say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 93.9% of votes cast for or against in favor at the meeting held June 3, 2026.
Which companies are in Aurinia Pharmaceuticals' peer group?
The disclosed peer group includes ANI Pharmaceuticals, Inc., Aquestive Therapeutics Inc., Arcutis Biotherapeutics Inc., ARS Pharmaceuticals Inc. and Collegium Pharmaceutical Inc., among others.
What is Aurinia Pharmaceuticals' chief executive pay ratio?
The company reported a chief executive pay ratio of 18:1 for fiscal 2025, against median employee compensation of $320,246.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Peter Greenleaf
Chief Executive Officer
◇—◇◇◇—◇◇
Max Colao
Former Chief Commercial Officer (8)
Departed during or after this year
◇—◇◇◇—◇◇
Max Donley
EVP, Operations and Strategy
◇—◇◇◇—◇◇
Joe Miller
Chief Financial Officer (7)
◇—◇◇◇—◇◇
Stephen Robertson
EVP, General Counsel, Corporate Secretary and Chief Compliance Officer (9)
◇—◇◇◇—◇◇
Neil Solomons
Former Chief Medical Officer (10)
Departed during or after this year
◇—◇◇◇—◇◇
Volker Knappertz
EVP, Research and Development (11)
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Peter Greenleaf
Former Chief Executive Officer
◇—◇—◇—◇◇
Matthew Donley
Former Chief Operating Officer
◇—◇—◇—◇◇
Joseph Miller
Former Chief Financial Officer
◇—◇—◇—◇◇
Stephen Robertson
Chief Legal Officer, Corporate Secretary and Chief Compliance Officer
◇—◇—◇—◇◇
Gregory Keenan
Former Chief Medical Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Peter Greenleaf
Former Chief Executive Officer
◇—◇—◇—◇◇
Matthew Donley
Former Chief Operating Officer
◇—◇—◇—◇◇
Joseph Miller
Former Chief Financial Officer
◇—◇—◇—◇◇
Stephen Robertson
Chief Legal Officer, Corporate Secretary and Chief Compliance Officer
◇—◇—◇—◇◇
Gregory Keenan
Former Chief Medical Officer
◇—◇—◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Peter Greenleaf
Former Chief Executive Officer
Departed during or after this year
◇—◇◇◇—◇◇
Matthew Donley
Former Chief Operating Officer
Departed during or after this year
◇—◇◇◇—◇◇
Stephen Robertson
Chief Legal Officer, Corporate Secretary and Chief Compliance Officer
◇—◇◇◇—◇◇
Joseph Miller
Former Chief Financial Officer
Departed during or after this year
◇—◇◇◇—◇◇
Gregory Keenan
Former Chief Medical Officer
Departed during or after this year
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Gregory KeenanPSU◇◇◇—◇—◇
Gregory KeenanOPTION◇——◇—◇◇
Joseph MillerPSU◇◇◇—◇—◇
Joseph MillerOPTION◇——◇—◇◇
Matthew DonleyPSU◇◇◇—◇—◇
Matthew DonleyOPTION◇——◇—◇◇
Peter GreenleafPSU◇◇◇—◇—◇
Peter GreenleafOPTION◇——◇—◇◇
Stephen RobertsonPSU◇◇◇—◇—◇
Stephen RobertsonOPTION◇——◇—◇◇
Fiscal 2022 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Peter GreenleafOption◇—◇2/28/2035
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Matthew DonleyRSU◇◇——
Option◇—◇2/28/2035
RSU◇◇——
RSU◇◇——
RSU◇◇——
Joseph MillerRSU◇◇——
Option◇—◇2/28/2035
RSU◇◇——
RSU◇◇——
RSU◇◇——
Stephen RobertsonRSU◇◇——
Option◇—◇2/28/2035
RSU◇◇——
RSU◇◇——
RSU◇◇——
Gregory KeenanOption◇—◇2/28/2035
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/6/2033
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Tina S. Nova, Ph.D
◇—◇———◇
Kathy Goetz
◇—◇———◇
Craig Johnson
Lead independent director
◇—◇———◇
Jeffrey Bailey
◇—◇———◇
Jill Leversage
◇—————◇
Dr. Karen Smith
◇—————◇
Dr. David R.W. Jayne
◇—————◇
Kevin Tang served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options.
Stock ownership guideline: Stock ownership guidelines for directors

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • ANI Pharmaceuticals, Inc. ANIP
  • Aquestive Therapeutics Inc. AQST
  • Arcutis Biotherapeutics Inc. ARQT
  • ARS Pharmaceuticals Inc. SPRY
  • Collegium Pharmaceutical Inc. COLL
  • Day One Biopharmaceuticals Inc. DAWN
  • Evolus Inc. EOLS
  • Innoviva Inc. INVA
  • Ironwood Pharmaceuticals Inc. IRWD
  • Lexicon Pharmaceuticals Inc. LXRX
  • Liquidia Corp symbol not shown
  • MiMedx Group Inc. MDXG
  • Pacira Biosciences Inc. PCRX
  • Phathom Pharmaceuticals Inc. PHAT
  • Sage Therapeutics Inc. SAGE
  • Siga Technologies Inc. SIGA
  • Tarsus Pharmaceuticals Inc. TARS
  • Travere Therapeutics, Inc. TVTX
  • Urogen Pharma Ltd. URGN
  • Y-mAbs Therapeutics, Inc. YMAB

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 3, 2026=◇◇◇
2024May 15, 2025=◇◇◇
2023June 14, 2024=◇◇◇
2022May 17, 2023=◇◇◇
2021May 17, 2022=◇◇◇
2020June 7, 2021=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Peter Greenleaf (Former Chief Executive Officer), FY2025 total compensation $5,858,590 (base salary $822,877) [exec_comp, SEC accession 0001600620-26-000039, filed 2026-04-21]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Aurinia Pharmaceuticals files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Aurinia Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Aurinia Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Aurinia Pharmaceuticals' disclosed peer group is defensible, who names Aurinia Pharmaceuticals back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
273 figures on this page: 267 cited to the filing that reported them, 6 calculated from figures it prints.
267 cited to the filing
6 calculated from the filing

Documents cited

  1. 0001600620-26-000053
    Item 5.07 Submission of Matters to a Vote of Security Holders.
  2. 0001600620-26-000039
    Director Compensation
  3. 0001600620-25-000057
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001600620-24-000087
    Item 5.07 Submission of Matters to a Vote of Security Holders
  5. 0001600620-23-000015
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001600620-23-000005
  7. 0001628280-22-015026
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001628280-21-012006
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Aurinia Pharmaceuticals executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/AUPH (accessed 2026).
Short form: data: Velarion

The Aurinia Pharmaceuticals brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
8 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Aurinia Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Aurinia Pharmaceuticals discloses

The companies named in AUPH's own disclosed peer group.

ANI Pharmaceuticals, Inc.Aquestive Therapeutics Inc.Arcutis Biotherapeutics Inc.ARS Pharmaceuticals Inc.Collegium Pharmaceutical Inc.Day One Biopharmaceuticals Inc.Evolus Inc.Innoviva Inc.Ironwood Pharmaceuticals Inc.Lexicon Pharmaceuticals Inc.MiMedx Group Inc.Pacira Biosciences Inc.Phathom Pharmaceuticals Inc.Sage Therapeutics Inc.Siga Technologies Inc.Tarsus Pharmaceuticals Inc.Travere Therapeutics, Inc.Urogen Pharma Ltd.Y-mAbs Therapeutics, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy